JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2024  1,200
2023  1,500
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 60(2026) N 2 p. 299-311; DOI 10.1134/S0026893325700748 Full Text

A.I. Andreev1,2, M.E. Neganova1,3, Yu.R. Aleksandrova1,3, D.I. Salikhova4,5, E.V. Belousova4,5, M.O. Shedenkova4,5, A.K. Sudina4,5, Ya.M. Maksimov4,5, E.A. Orlova1, M.A. Lapshina1, V.S. Popov6,7, E.A. Ahremenko1,2, D.V. Goldshtein4, A.A. Ustyugov1, V.O. Nebogatikov1*

Glial Progenitor Cell Therapy Improves Mitochondrial Function in the Hippocampus of 5xFAD Mice, but Does Not Restore the Multiscale Structure of Behavioral Stress Response

1Institute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Moscow oblast, 142432 Russia
2Perm State National Research University, Perm, 614068 Russia
3Nesmeyanov Institute of Organoelement Compounds, Russian Academy of Sciences, Moscow, 119334 Russia
4Bochkov Medical Genetics Research Center, Moscow, 115522 Russia
5Research Institute of Molecular and Cellular Medicine, RUDN University, Moscow, 117198 Russia
6Center of Regenerative Medicine, Medical Research and Education Institute, Moscow State University, Moscow, 119234 Russia
7Faculty of Fundamental Medicine, Medical Research and Education Institute, Moscow State University, Moscow, 119234 Russia


*nebogatikov@ipac.ac.ru
Received - 2025-05-31; Revised - 2025-06-26; Accepted - 2025-07-02

Cell therapy is increasingly used to treat a variety of medical conditions, including cancer, immune system disorders, and neurodegeneration. Stem cells secrete growth factors, signaling molecules, and extracellular vesicles, that can be used to treat neurological diseases and promote neuronal regeneration. Transgenic 5xFAD mice, which are a model for Alzheimer's disease (AD), were used in this study. The mice were 7 months old and received retro-orbital injections of glial progenitor cells (GPCs) once a week for 4 months. At 11 months, their behavior was analyzed using a multichannel actigraphy system. Brain tissues from the cortex, hippocampus, and midbrain were collected for postmortem analysis of mitochondrial respiratory chain enzyme activity. The results showed that the GPCs injection significantly improved the response of the hippocampal p2 mitochondrial fraction in 5xFAD mice to succinate, reaching a level observed in control animals. A similar trend was also observed for the cytochrome c oxidase complex. The oxygen consumption rate of mitochondria did not differ from that of clinically healthy mice after ascorbate/N,N,N',N'-tetramethyl-p-phenylenediamine dihydrochloride administration. A similar decrease in the efficiency of the electron transport chain was detected in the midbrain of 5xFAD mice, but no recovery was observed after GPCs treatment. Behavioral differences between non-transgenic and transgenic groups were observed in a multiparameter analysis using the actigraphy system. The behavior of transgenic mice in the treated and untreated groups was similar, while the behavior of non-transgenic mice varied. Additional analysis of locomotor activity and transient events in particular revealed that the activity of the GPCs-treated 5xFAD mice was differed fundamentally compared to other groups. Specifically, GPCs-treated mice exhibited greater number of transitions between intermediate activity states. In contrast, untreated mice showed transitions between extreme activity states, such as from low to high activity or vice versa. These findings suggest that changes in behavior and activity of the AD mice may be associated not only with hippocampal dysfunction, but also with disruptions in midbrain structures.

Alzheimer's disease, glial progenitor cells, transgenic animals, spontaneous motor activity, mitochondrial activity



JMB-FOOTER RAS-JOURNALS